Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-05-15
Target enrollment:
Participant gender:
Summary
This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and
safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab
(BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects
who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single agent
rituximab is permitted, prior involved-field radiotherapy is permitted).